Actionnariat et activité des initiés pour Cellectis S.A. (CLLS): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $1.38 |
| Capitalisation | $138M |
| Bourse | NASDAQ |
| Pays | FR |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $290.5M | $297.0M | $451.9M | $360.9M | $241.1M | $185.6M | $89.8M | $136.7M | $143.3M | $63.6M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | $27.1M | $499000 | $7.9M | $67.1M | $117.1M | $145.1M |
| Créances | $3.6M | $4.6M | $22.1M | $15.3M | $19.2M | $31.1M | $17.6M | $23.1M | $23.0M | $25.3M |
| Stocks | $117790 | $250000 | $275000 | $2.9M | $1.6M | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $311.8M | $323.2M | $487.6M | $391.5M | $315.4M | $225.4M | $143.8M | $233.0M | $287.1M | $236.2M |
| Immobilisations Corporelles | $16.9M | $7.2M | $10.0M | $69.3M | $145.5M | $148.3M | $107.9M | $92.7M | $75.9M | $62.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | $1.3M | $1.4M | $1.3M | $1.1M | $1.6M | $1.9M | $718000 | $672000 | $1.1M | $535000 |
| Actifs Totaux | $330.7M | $332.9M | $500.8M | $467.5M | $469.5M | $382.1M | $261.2M | $334.3M | $383.5M | $324.7M |
| Dettes Fournisseurs | $9.7M | $9.5M | $15.9M | $29.3M | $24.6M | $23.8M | $21.5M | $19.1M | $18.7M | $17.3M |
| Dette à Court Terme | $1.7M | 0 | 0 | 0 | 0 | $2.2M | $5.0M | $5.2M | $4.8M | $18.2M |
| Passifs Courants | $56.0M | $43.5M | $46.9M | $62.6M | $52.0M | $49.3M | $63.0M | $155.1M | $166.3M | $145.8M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | $24.2M | $18.8M | $13.6M | $28.4M | $44.0M | $74.0M |
| Passifs Totaux | $56.6M | $47.0M | $50.6M | $112.0M | $160.6M | $145.6M | $135.3M | $249.6M | $252.5M | $248.8M |
| Réserves | -$229.8M | -$351.3M | -$405.3M | -$508.5M | -$587.0M | -$698.3M | -$439.5M | -$405.8M | -$329.6M | -$334.1M |
| Capitaux Propres | $272.2M | $266.8M | $409.3M | $315.1M | $283.8M | $221.3M | $118.0M | $84.7M | $131.0M | $75.9M |
| Dette Totale | $1.8M | $34000 | $1.4M | $47.6M | $106.7M | $100.9M | $75.8M | $85.1M | $91.5M | $119.9M |
| Dette Nette | -$288.7M | -$296.9M | -$450.5M | -$313.3M | -$161.6M | -$85.3M | -$21.9M | -$118.8M | -$168.8M | -$88.8M |
| Fonds de Roulement | $255.7M | $279.7M | $440.8M | $328.9M | $263.3M | $176.1M | $80.8M | $77.9M | $120.8M | $90.5M |
Santé financière
| Dette / Capitaux propres | 2.06 |
| Ratio de liquidité | 1.37 |
Rentabilité
| Rentabilité des capitaux propres | -94.14% |
| Rentabilité du capital investi | -41.00% |
| Rentabilité des actifs | -24.41% |
| Marge brute | 74.68% |
| Marge opérationnelle | -107.92% |
| Marge nette | -115.36% |
Entreprises liées: ACIU · ALDX · AMRN · ANRO · DBVT · DRTS · KRRO
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de CLLS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions